Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13245474 | 0.86 | GAA (0.57) | TAS1R3TAS1R1L3MBTL1ALDH1A1GAA | |
| SCHEMBL13245476 | 0.85 | L3MBTL1 (0.50) | TAS1R3TAS1R1L3MBTL1ALDH1A1GAA | |
| SCHEMBL13245366 | 0.84 | TAS1R3 (0.52) | TAS1R3TAS1R1L3MBTL1ALDH1A1GAA | |
| SCHEMBL13245482 | 0.82 | TAS1R3 (0.51) | TAS1R3TAS1R1L3MBTL1ALDH1A1GAA | |
| SCHEMBL12064262 | 0.80 | TAS1R3 (0.45) | TAS1R3TAS1R1ALDH1A1ACACB | |
| SCHEMBL13654203 | 0.80 | TAS1R3 (0.45) | TAS1R3TAS1R1ALDH1A1ACACB | |
| SCHEMBL404219 | 0.80 | TAS1R3 (0.45) | TAS1R3TAS1R1ALDH1A1ACACB | |
| SCHEMBL15747119 | 0.79 | TAS1R3 (0.78) | TAS1R3TAS1R1 | |
| SCHEMBL13245479 | 0.79 | L3MBTL1 (0.45) | TAS1R3TAS1R1L3MBTL1ALDH1A1GAA | |
| SCHEMBL13245484 | 0.78 | KDM4E (0.47) | TAS1R3TAS1R1L3MBTL1ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, ABCB11 | TAS1R3 4086/4885TAS1R1 3410/4885L3MBTL1 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.